Latest news

Elixirgen Therapeutics successfully concludes pre-IND meeting with FDA

BALTIMORE, May 30, 2017 – Elixirgen Therapeutics has successfully concluded its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for inherited bone marrow failure syndromes (IBMFS), including Dyskeratosis Congenita (DC) and Fanconi Anemia (FA).

Elixirgen, LLC forms subsidiary company Elixirgen Therapeutics, LLC

BALTIMORE, January 5, 2017 – Elixirgen, LLC announced that it has formed its therapeutics-focused subsidiary company, Elixirgen Therapeutics, LLC, on January 5, 2017. Elixirgen Therapeutics is a company that is dedicated to finding cures and therapies for genetic diseases, and then developing them into drugs to treat patients. The company’s experienced team of researchers has a wide […]

Elixirgen awarded SBIR Phase I grant

BALTIMORE, August 5, 2016 – Elixirgen has awarded the Small Business Innovation Research (SBIR) Phase I Grant from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH).

See all our news